Study protocol

Treatment with inhaled corticosteroids (ICS) is a widely used treatment in chronic obstructive pulmonary disease. The main effects include a reduction in the number of exacerbations and , for some patients, an increase in expected mortality. ...

Treatment with inhaled corticosteroids (ICS) is a widely used treatment in chronic obstructive pulmonary disease. The main effects include a reduction in the number of exacerbations and , for some patients, an increase in expected mortality. Unfortunately, ...
Study protocol

Introduction Treatment with inhaled corticosteroids (ICS) is a widely used treatment in chronic obstructive pulmonary disease. The main effects include a reduction in the number of exacerbations and , for some patients, an increase in expected mortality. Unfortunately, the treatment is also linked to an increased risk of pneumonia , and very little is known about which patients experience this ...
Introduction Treatment with inhaled corticosteroids (ICS) is a widely used treatment in chronic obstructive pulmonary disease. The main effects include a reduction in the number of exacerbations ...

PDF Study protocol
Study protocol : pneumonia and inhaled corticosteroid treatment patterns in chronic obstructive pulmonary disease - a cohort study using sequence analysis (PICCS) Allan Klitgaard ,1,2 Rikke Ibsen,3 Ole Hilberg,1,2 Anders Løkke1,2
Abstract Introduction Treatment with inhaled corticosteroids (ICS) is a widely used treatment in chronic obstructive pulmonary disease. The main effects include a reduction in the number of exacerbations and , for some patients, an increase in expected mortality.

Study protocol
Inhaled corticosteroid (ICS) treatment is one of the medical treatments used in chronic obstructive pulmonary disease (COPD). 1 2 The main effect of ICS is a reduction in acute exacerbations of COPD, and the treatment has shown statistically significant effects on quality of life and mortality. 3 However, the treatment is associated with side ...
We aimed to assess the association between ICSs treatment and pneumonia risk in COPD patients, and the impact of medication details and baseline characteristics of patients on the association.

Hydrocortisone in Severe Community
We conducted the Community-Acquired Pneumonia : Evaluation of Corticosteroids (CAPE COD) trial to evaluate whether early treatment with hydrocortisone reduced mortality at 28 days among patients ...








Despite advances in treatment and the expansion of standard care, pneumonia remains a major cause of mortality. It frequently leads to complications such as septic shock and acute respiratory distress syndrome (ARDS), both of which carry high fatality rates. Although antimicrobial therapy is the cornerstone of treatment , additional supportive care and adjunctive therapies, such as ...